Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Joerg Herrmann MD

Joerg Herrmann MD

Professor of Medicine, Mayo Graduate School of Medicine, Rochester, Minnesota

Dr. Joerg Herrmann is Professor of Medicine at the Mayo Graduate School of Medicine, and he serves as the Director of the Cardio-Oncology Clinic and the Research Director of the Ischemic Heart Disease Program.

His research primarily focuses on the interaction of cancer and heart disease, particularly the potentially harmful side effects of cancer therapies on the cardiovascular system. Beyond cardio-oncology, his research interests extend to cardiac biomarkers, immune-metabolism, periprocedural myocardial infarction, and vascular diseases, particularly the development of atherosclerotic plaques and associated complications.

Dr. Herrmann serves as a reviewer for more than 30 journals, including all major cardiovascular journals. He currently is the chair of the Scientific Committee of the International Cardio-Oncology Society and is an associate editor of several journals including the European Heart Journal (EHJ), EHJ Open, Trends in Cardiovascular Medicine, and the International Journal of Cardiology, among others. He is also a regular contributor to Braunwald's Heart Disease, the associate editor of Trends in Cardiovascular Medicine, and the editor of the Cardio-Oncology Companion Book to Braunwald’s Heart Disease as well as the textbook Clinical Cardio-Oncology.

Disclosures

  • Consulting/advisory boards: ARIAD Pharmaceuticals (2014 and 2016 Ponatinib in CML Cardio-Oncology Advisory Board meeting); Amgen (2016 Carfilzomib Advisory Board meeting); Bristol-Myers Squib (Institute for Cardio-Oncology Advisory Panel); Pfizer
  • Grants/research: NIH

Recent Contributions to PracticeUpdate:

  1. ESC 2022: Recommendations From Dr. Joerg Herrmann
  2. Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors
  3. SGLT2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines
  4. FFR-Guided Stenting or Coronary Bypass Surgery for Better Quality of Life
  5. Preservation of Cardiac Function After Myocardial Infarction
  6. FFR-Guided vs IVUS-Guided PCI in Intermediate Coronary Artery Stenosis
  7. ACC 2022: Recommendations From Dr. Joerg Herrmann
  8. 2021 Top Story in Cardiology: EMPEROR-Preserved—Empagliflozin in HFpEF
  9. Similar 5-Year All-Cause Death Between PCI and CABG
  10. ESC 2021: Recommendations From Dr. Joerg Herrmann

Elsewhere

Most Read This Week

Recently Updated